Skip to main content
. 2016 May 21;7(25):38551–38565. doi: 10.18632/oncotarget.9535

Figure 3. Identification of AR-eRNAs whose expression is altered in LNCaP and C4-2 cells after long-term treatment with enzalutamide.

Figure 3

A. Heat maps show AR-eRNAs differentially regulated in LNCaP and C4-2 cells after long-term treatment with enzalutamide. B-E. Screenshots of the UCSC genome browser show AR-eRNAs (right panel) and related mRNAs (left panel) expression in the loci of NCAM2 (B) FTO (C) MARC1 (D) and LUZP2 (E) The area highlighted in orange indicates the enhancer region expressing AR-eRNA in each locus.